Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide-for type 1 diabetes.

Tatjana Nikolic Jaap J Zwaginga Bas S Uitbeijerse Nicky J Woittiez Eelco J de Koning Henk-Jan Aanstoot Bart O Roep

Lancet Diabetes Endocrinol

Immunomodulation and Regenerative Cell Therapy, Leiden University Medical Center, 2333 ZA Leiden, Netherlands; Department of Diabetes Immunology, Diabetes and Metabolism Research Institute, Beckman Research Institute at City of Hope, Duarte, CA, USA.

Published: June 2020

Download full-text PDF	Source
http://dx.doi.org/10.1016/S2213-8587(20)30104-2	DOI Listing

Publication Analysis

Top Keywords

safety feasibility

feasibility intradermal

intradermal injection

injection tolerogenic

tolerogenic dendritic

dendritic cells

cells pulsed

pulsed proinsulin

proinsulin peptide-for

peptide-for type

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!